Impact of telmisartan in modifying vascular risk
Jean-Philippe Baguet, Olivier Ormezzano, Gilles Barone-RochetteClinique de Cardiologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, FranceAbstract: Telmisartan, a selective angiotensin II type 1 receptor blocker (ARB), has been investigated in many trials, in particular, in order to asse...
Saved in:
Main Authors: | Jean-Philippe Baguet (Author), Olivier Ormezzano (Author), Gilles Barone-Rochette (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2010-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dissolution rate improvement of telmisartan through modified MCC pellets using 32 full factorial design
by: Hetal Patel, et al.
Published: (2016) -
The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics
by: Jiagen Wen, et al.
Published: (2019) -
Telmisartan Self-Nanoemulsifying Drug Delivery System, Compared With Standard Telmisartan, More Effectively Improves Hepatic Fibrosis in Rats
by: Hussam Murad, et al.
Published: (2020) -
Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study
by: Bong-Joon Kim, et al.
Published: (2022) -
TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015)